Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists’ armamentarium and to appreciate more fully its long-term safety.
Intravenous golimumab in rheumatoid arthritis
Expert Review of Clinical Immunology ; 10 , 7 ; 823-830
2014-07-01
8 pages
Aufsatz (Zeitschrift)
Elektronische Ressource
Englisch
Gouty arthritis masquerading as rheumatoid arthritis or vice versa
Elsevier | 1978
|New Therapeutic Approaches for Rheumatoid Arthritis
British Library Online Contents | 2005
|Muehrcke Lines Associated to Active Rheumatoid Arthritis
British Library Online Contents | 2013
|A Case of Methimazole-Induced Chronic Arthritis Masquerading as Seronegative Rheumatoid Arthritis
British Library Online Contents | 2014
|Tuberculous Peritonitis in a Patient With Rheumatoid Arthritis
British Library Online Contents | 2014
|